Proven device combination for ChEVAR.
EnChEVAR with EndurantTM II/IIs system + RadiantTM covered stent demonstrates durable clinical outcomes (mean f/u 24.6 ± 17.4 months)1:
- 1.6% new late onset type Ia endoleak
- 95.7% primary chimney graft patency
Proven, safe, and effective way to lengthen aortic sealing zones
Learn how EnChEVAR with EndurantTM II/IIs system + RadiantTM stent provides durable outcomes in challenging hostile sealing zones.
EnChEVAR deployment
Step-by-step deployment of the EndurantTM II/IIs and RadiantTM stent grafts for ChEVAR.||
EnChEVAR live case
Explore a unique real live case performed by Prof. Fazzini in a 3 min video.
ENCHANT Trial3 1-year data release
EnChEVAR (Endurant II/IIs stent graft system + Radiant† balloon-expandable covered stent) analysis (n = 62)3
ENCHANT is a multicentre, prospective, single-arm, post-market study to assess the clinical outcomes, safety, and performance of the Endurant II/IIs system used with balloon-expandable covered stents for treatment of juxtarenal aortic aneurysms with a short infrarenal neck in a real-world setting.
Key outcomes of the one year Kaplan-Meier analyses.
- 29 centres in EU and Russia
- Freedom from all-cause mortality: 87.0 ± 4.3%
- Freedom from aneurysm rupture: 100%
- Freedom from conversion: 100%
- Freedom from all secondary procedures: 88.0 ± 4.3%
- Freedom from secondary procedures to treat type la endoleak: 100%
97.6% chimney graft patency at one year.
One year sac status by Core Lab (n = 41)‡
- 2.4% sac increase
- 68.3% sac stable
- 29.3% sac decrease
PROTAGORAS study
The PROTAGORAS study1 evaluated the performance of the EndurantTM II/IIs stent graft for patients with pararenal pathologic processes that were treated by the chemistry/snorkel endovascular technique.
Standardised use of the EndurantTM II/IIs stent graft system and RadiantTM covered stent for ChEVAR demonstrated:
N = 128 patients1
- 24.6 months mean radiologic follow-up (range, 0–61 months)
- 100% technical success
- New late onset of type Ia endoleaks: 1.6%
- Primary patency of chimney grafts: 95.7%
- AAA sac diameter regression/stability: 90.6%
- Freedom from chimney graft-related reinterventions: 93.1%
RadiantTM covered stent shows significantly better performance in ChEVAR compared to other grafts, with 94.6% patency at midterm compared to 84.1% patency with other covered stents.2
View brochure for full details.
Our experts tell it best. Watch their testimonials
How does standardization improve clinical results?
Dr. Fazzini explains the benefits of the combination of EndurantTM II/IIs system and RadiantTM stent: safer procedure, shorter recovery times, and lower of reintervention rate.
Our experts tell it best. Clinician experiences on EnChEVAR
Prof. Reijnen and Prof. Donas share their clinical experience about EnChEVAR technique with EndurantTM II/IIs system and RadiantTM covered stent.
Use this tool to see full ordering information and plan case specifics such as sizing and placement.
Preparing for the case
Recommended ancillary equipment§:
Soft wire for easy access to renal arteries
- 0.035” soft Terumo GLIDEWIRE™* hydrophilic-coated guidewire
Renal wire balanced between stiffness and flexibility; atraumatic short tip
- Cook Rosen™* wire guide
7 F sheath, 90 cm length with atraumatic tip for renal entry
- Medtronic TourGuide™ steerable sheath 7 F, 90 cm
- Cook Flexor™* Shuttle™* guiding sheath, Terumo Destination™* guiding sheath
Shorter 16 F sheath or larger may be used for access during a two-chimney case.
Catheter — 5 F, minimum length of 110 cm to 125 cm
Must be able to pass through and extend beyond 90 cm sheath; variety of angles to support renal cannulation; vertebral multipurpose.
Balloons
- Medtronic Reliant™ stent graft balloon catheter to achieve good conformability of the Medtronic Endurant II/IIs stent graft system with the aortic wall and the renal stents
- Medtronic Admiral Xtreme™ PTA balloon catheter OTW 0.035“ assist in access to renal (4 mm x 40 mm)
Inflation devices
- 20 cc syringe
- 20 cc inflation device equipped with manometer
Related pages
Aortic catalog
Choose from a complete portfolio of market-leading aortic vascular therapies to treat aneurysm disease.
*
™Third-party brands are trademarks of their respective owners.
†
Patients in this dataset were treated with Advanta V12, which was re-labelled as Radiant and received CE mark approval in September 2022 for use in ChEVAR.
‡
Denominator is the number of subjects with Core Lab-reported maximum aneurysm diameter at both one month post-implant and one-year follow-up.
§
Other covered stents include: GORE Viabahn®*, Bentley BeGraft™*, BD LifeStream™*.
||
All indications related to the EndurantTM II/IIs and RadiantTM stent grafts are not approved globally. Please check your local regulatory approval status. Refer to the complete Instructions for Use manual of the EndurantTM II/IIs and RadiantTM stent grafts for the indications approved in your geography.
References
1
Donas KP, Torsello GB, Piccoli G, et al. The PROTAGORAS study to evaluate the performance of the Endurant stent graft for patients with pararenal pathologic processes treated by the chimney/snorkel endovascular technique. J Vasc Surg. January 2016;63(1):1–7.
2
Pitoulias GA, Torsello G, Austermann M, et al. Outcomes of elective use of the chimney endovascular technique in pararenal aortic pathologic processes. J Vasc Surg. February 2021;73(2):433–442.
3
Prof. Giovanni Torsello. "ENCHANT Trial interim analysis: Endurant ChEVAR technique for juxtarenal aneursyms. "Presented at LINC, June 8, 2023; Leipzig, DE.
Brief statement: See the device manual for detailed information regarding the instructions for use, the implant procedure, indications, contraindications, warnings, precautions, and potential adverse events. For further information, contact your local Medtronic representative and/or consult the Medtronic website at medtronic.eu. For applicable products, consult instructions for use on www.medtronic.com/manuals. Manuals can be viewed using a current version of any major internet browser. For best results, use Adobe Acrobat® Reader with the browser.
Important Reminder: This information is intended only for users in markets where Medtronic products and therapies are approved or available for use as indicated within the respective product manuals. Content on specific Medtronic products and therapies is not intended for users in markets that do not have authorization for use.